Robert M Prins

Title(s)Professor-in-Residence, Neurosurgery
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Professor-in-Residence, Molecular and Medical Pharmacology


    Collapse Research 
    Collapse Research Activities and Funding
    Identification and cloning of neoantigen-specific T cells for GBM immunotherapy
    NIH R01CA222695Apr 1, 2019 - Mar 31, 2024
    Role: Principal Investigator
    Immunotherapeutic targeting of the Glioblastoma Mutanome
    NIH R21CA186004Jan 16, 2015 - Dec 31, 2017
    Role: Principal Investigator
    Optimizing Induction Conditions for Immunotherapeutic CTL
    NIH R01CA154256Jul 13, 2010 - May 31, 2016
    Role: Principal Investigator
    CNS Anti-tumor immunity induced by dendritic cell vaccination and TLR agonists
    NIH R01CA123396Apr 1, 2007 - Jul 31, 2012
    Role: Principal Investigator
    Immune targeting of melanoma-associated antigens in glioma
    NIH K01CA111402Jul 1, 2006 - Jun 30, 2012
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Is there a role for neoadjuvant anti-PD-1 therapies in glioma? Curr Opin Neurol. 2021 Oct 04. Sun L, Lai T, Prins RM. PMID: 34608074.
      View in: PubMed   Mentions:    Fields:    
    2. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun. 2021 06 29; 12(1):4031. Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. PMID: 34188042.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375. Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H. PMID: 33367885.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    4. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 10 14; 22(10):1425-1438. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. PMID: 32615600.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    5. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245. Ladomersky E, Zhai L, Lauing KL, Bell A, Xu J, Kocherginsky M, Zhang B, Wu JD, Podojil JR, Platanias LC, Mochizuki AY, Prins RM, Kumthekar P, Raizer JJ, Dixit K, Lukas RV, Horbinski C, Wei M, Zhou C, Pawelec G, Campisi J, Grohmann U, Prendergast GC, Munn DH, Wainwright DA. PMID: 32546647.
      View in: PubMed   Mentions: 11     Fields:    
    6. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro Oncol. 2019 09 06; 21(9):1184-1196. Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. PMID: 31066901.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    7. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Sci Rep. 2019 02 26; 9(1):2846. Chakhoyan A, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. PMID: 30808879.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    8. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. PMID: 30742122.
      View in: PubMed   Mentions: 253     Fields:    Translation:HumansCells
    9. Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. Front Immunol. 2019; 10:121. Owens GC, Garcia AJ, Mochizuki AY, Chang JW, Reyes SD, Salamon N, Prins RM, Mathern GW, Fallah A. PMID: 30761153.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    10. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clin Cancer Res. 2019 03 15; 25(6):1913-1922. Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A, Antonios J, Garcia A, Kotecha N, Bayless N, Nathanson D, Wang A, Everson R, Yong WH, Cloughesy TF, Liau LM, Herold-Mende C, Prins RM. PMID: 30498094.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    11. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 08 15; 24(16):3845-3856. Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML. PMID: 30018119.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    12. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 06 29; 16(1):179. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29958537.
      View in: PubMed   Mentions: 4     Fields:    
    13. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 05 29; 16(1):142. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29843811.
      View in: PubMed   Mentions: 110     Fields:    Translation:HumansCellsCTClinical Trials
    14. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018; 6:4. Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI. PMID: 29692895.
      View in: PubMed   Mentions: 19  
    15. Precision Medicine in Pediatric Neurooncology: A Review. ACS Chem Neurosci. 2018 01 17; 9(1):11-28. Mochizuki AY, Frost IM, Mastrodimos MB, Plant AS, Wang AC, Moore TB, Prins RM, Weiss PS, Jonas SJ. PMID: 29199818.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    16. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathol. 2018 Jan; 35(1):1-9. Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, Gordon LK, Wadehra M, Yang I. PMID: 28887715.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10220-10225. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. PMID: 28874539.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    18. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. J Neurooncol. 2017 Aug; 134(1):29-40. Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios JP, Kasahara N, Yang I, Prins RM, Braun J, Gordon LK, Wadehra M. PMID: 28597184.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    19. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 06 01; 19(6):796-807. Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 28115578.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    20. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 07; 1(10). Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 27453950.
      View in: PubMed   Mentions: 62     Fields:    
    21. TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunol Res. 2016 05; 4(5):412-418. Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins HS, Yong WH, Davidson TB, Li G, Liau LM, Prins RM. PMID: 26968205.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    22. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol. 2016 Mar; 18(3):368-78. Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM. PMID: 26330563.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    23. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 2015 Sep 01; 22(3):508-15. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung ME, Reue K, Huang J. PMID: 26190651.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    24. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol. 2015 Nov; 17(11):1514-24. Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. PMID: 26113557.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    25. Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes. J Vis Exp. 2015 Feb 11; (96). Erickson KL, Hickey MJ, Kato Y, Malone CC, Owens GC, Prins RM, Liau LM, Kasahara N, Kruse CA. PMID: 25741775.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    26. Dominant B-cell epitopes from cancer/stem cell antigen SOX2 recognized by serum samples from cancer patients. Am J Clin Exp Immunol. 2014; 3(2):84-90. Shih J, Rahman M, Luong QT, Lomeli SH, Riss J, Prins RM, Gure AO, Zeng G. PMID: 25143868.
      View in: PubMed   Mentions: 2  
    27. Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer. 2014; 2:10. Everson RG, Jin RM, Wang X, Safaee M, Scharnweber R, Lisiero DN, Soto H, Liau LM, Prins RM. PMID: 24883189.
      View in: PubMed   Mentions: 16     Fields:    
    28. The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. J Immunother Cancer. 2014; 2:8. Lisiero DN, Soto H, Everson RG, Liau LM, Prins RM. PMID: 25054063.
      View in: PubMed   Mentions: 19     Fields:    
    29. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res. 2013 May; 33(5):2047-56. Lasky JL, Panosyan EH, Plant A, Davidson T, Yong WH, Prins RM, Liau LM, Moore TB. PMID: 23645755.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    30. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 2013 May 01; 73(9):2850-62. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, Kidani Y, Pourzia AL, Akhavan D, Lisiero DN, Komisopoulou E, Henkin AH, Soto H, Chamberlain BT, Vergnes L, Jung ME, Torres JZ, Liau LM, Christofk HR, Prins RM, Mischel PS, Reue K, Graeber TG, Bensinger SJ. PMID: 23440422.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    31. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013 Feb; 36(2):152-7. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. PMID: 23377664.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    32. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 03; 104(19):1458-69. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. PMID: 22945948.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    33. Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies. Neurosurg Clin N Am. 2012 Jul; 23(3):451-8. Yang J, Nagasawa DT, Spasic M, Amolis M, Choy W, Garcia HM, Prins RM, Liau LM, Yang I. PMID: 22748657.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    34. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One. 2012; 7(4):e32614. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM. PMID: 22485134.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCellsPHPublic Health
    35. Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. Am J Transl Res. 2012; 4(1):114-26. Hickey MJ, Malone CC, Erickson KE, Gomez GG, Young EL, Liau LM, Prins RM, Kruse CA. PMID: 22347526.
      View in: PubMed   Mentions: 8  
    36. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 07; 9:192. Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM. PMID: 22060015.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    37. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012 Mar; 107(1):197-205. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. PMID: 22015945.
      View in: PubMed   Mentions: 118     Fields:    Translation:Humans
    38. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. PMID: 22059152.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansAnimalsCells
    39. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model. J Immunol. 2011 May 01; 186(9):5068-77. Lisiero DN, Soto H, Liau LM, Prins RM. PMID: 21430221.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    40. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011 Mar 15; 17(6):1603-15. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. PMID: 21135147.
      View in: PubMed   Mentions: 189     Fields:    Translation:HumansCellsCTClinical Trials
    41. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 2010 Oct 14; 8:100. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, Kruse CA. PMID: 20946667.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    42. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010 Jun 17; 465(7300):966. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. PMID: 20559394.
      View in: PubMed   Mentions: 160     Fields:    Translation:Humans
    43. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. PMID: 20009104.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCells
    44. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10; 462(7274):739-44. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. PMID: 19935646.
      View in: PubMed   Mentions: 1332     Fields:    Translation:HumansCells
    45. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009 Nov 15; 69(22):8693-9. Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A. PMID: 19861533.
      View in: PubMed   Mentions: 70     Fields:    Translation:AnimalsCells
    46. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12932-7. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. PMID: 19625624.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansAnimalsCells
    47. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother. 2009 May; 58(5):699-708. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A. PMID: 18807035.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    48. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008 Jul 31; 359(5):539-41. Prins RM, Cloughesy TF, Liau LM. PMID: 18669440.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCellsCTClinical Trials
    49. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008 Sep; 57(9):1279-89. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM. PMID: 18253732.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    50. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther. 2007 Jul; 15(7):1390-9. Kimura T, Koya RC, Anselmi L, Sternini C, Wang HJ, Comin-Anduix B, Prins RM, Faure-Kumar E, Rozengurt N, Cui Y, Kasahara N, Stripecke R. PMID: 17505480.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCellsPHPublic Health
    51. NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol. 2006 Dec 15; 177(12):8448-55. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A. PMID: 17142742.
      View in: PubMed   Mentions: 26     Fields:    Translation:AnimalsCells
    52. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev Neurother. 2006 Oct; 6(10):1481-94. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. PMID: 17078788.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    53. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Neurosurgery. 2006 Jan; 58(1):169-78; discussion 169-78. Prins RM, Bruhn KW, Craft N, Lin JW, Kim CH, Odesa SK, Miller JF, Liau LM. PMID: 16385341.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCellsPHPublic Health
    54. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006 Jan 01; 176(1):157-64. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. PMID: 16365406.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansAnimalsCells
    55. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol Res. 2005 Oct; 27(7):692-702. Khan-Farooqi HR, Prins RM, Liau LM. PMID: 16197806.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    56. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 01; 11(15):5515-25. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. PMID: 16061868.
      View in: PubMed   Mentions: 216     Fields:    Translation:HumansCellsCTClinical Trials
    57. Cellular immunity and immunotherapy of brain tumors. Front Biosci. 2004 Sep 01; 9:3124-36. Prins RM, Liau LM. PMID: 15353342.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    58. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity. J Immunol. 2004 Feb 01; 172(3):1602-11. Prins RM, Incardona F, Lau R, Lee P, Claus S, Zhang W, Black KL, Wheeler CJ. PMID: 14734741.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    59. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg. 2004 Feb; 100(2):310-9. Yang I, Kremen TJ, Giovannone AJ, Paik E, Odesa SK, Prins RM, Liau LM. PMID: 15086239.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    60. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003 Dec 01; 63(23):8487-91. Prins RM, Odesa SK, Liau LM. PMID: 14679014.
      View in: PubMed   Mentions: 45     Fields:    Translation:AnimalsCells
    61. Immunology and immunotherapy in neurosurgical disease. Neurosurgery. 2003 Jul; 53(1):144-52; discussion 152-3. Prins RM, Liau LM. PMID: 12823883.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    62. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. J Neuroimmunol. 2003 Jul; 140(1-2):49-60. Graf MR, Prins RM, Poulsen GA, Merchant RE. PMID: 12864971.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    63. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother. 2002 Jun; 51(4):190-9. Prins RM, Scott GP, Merchant RE, Graf MR. PMID: 12012106.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCellsPHPublic Health
    64. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination. Cancer Immunol Immunother. 2002 Jun; 51(4):179-89. Graf MR, Prins RM, Hawkins WT, Merchant RE. PMID: 12012105.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCellsPHPublic Health
    Robert's Networks
    Concepts (318)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (52)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-866-g4098221c on PROFILES-PWEB01.

    Copyright © The Regents of the University of California